The Impact of Comorbidities on the Treatment Outcome in Patients With Severe Covid-19-Associated Pneumonia
Open Access
- 14 April 2025
- journal article
- Published by The Scientific and Practical Society of Emergency Medicine Physicians in Russian Sklifosovsky Journal "Emergency Medical Care"
- Vol. 14 (1) , 81-88
Abstract
BACKGROUND. A significant role in the course and outcome of COVID-19, alongside other clinical and laboratory factors, is played by comorbidities.THE AIM OF THE STUDY. We studied the impact of comorbidities on the course and outcomes of severe COVID-19-associated pneumonia.MATERIAL AND METHODS. The study was conducted at the Yakut Republican Clinical Hospital. We analyzed treatment outcomes of 450 patients with severe COVID-19-associated pneumonia who were hospitalized in the intensive care unit. An observational case-control study was conducted, in accordance with the research objective, comorbidities were analyzed in detail in two groups of patients: survivors — 144 (32.0%) and deceased — 306 (68.0%). The endpoint of the study was a fatal outcome. The modified Charlson comorbidity index was used to assess the patients’ comorbidity status.RESULTS. The study revealed the presence of concomitant pathology in 446 (99.1%) patients. 57 (12.7%) patients had two concomitant diseases, 369 (82%) patients had three or more pathologies. A statistically significant impact on the risk of death for the following combinations of comorbid conditions were found: chronic central nervous system diseases with chronic kidney disease; hypertension with chronic kidney disease; coronary heart disease with chronic kidney disease; severe obesity (class III) with coronary heart disease and chronic kidney disease; severe obesity (class III) with type 2 diabetes mellitus. The mortality rate of patients increases linearly with the growth of the Charlson comorbidity index (pCONCLUSION. The obtained data indicate a significant increase in the risk of death in patients with severe COVID-19-associated pneumonia in the presence of comorbidities. Therefore, when predicting the outcome and improving the treatment results of this category of patients, one should take into account the patient’s comorbidity.Keywords
This publication has 12 references indexed in Scilit:
- Prevalence of hypertension and associated risks in hospitalized patients with COVID-19: a meta-analysis of meta-analyses with 1468 studies and 1,281,510 patientsSystematic Reviews, 2022
- COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment – A narrative reviewBest Practice & Research Clinical Anaesthesiology, 2021
- Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysisHeart, 2020
- Age-specific mortality and immunity patterns of SARS-CoV-2Nature, 2020
- Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020Cardiovascular Therapy and Prevention, 2020
- Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysisAging, 2020
- Renal complications in COVID-19: a systematic review and meta-analysisAnnals of Medicine, 2020
- New coronavirus disease (COVID-19) and cardiovascular diseaseComplex Issues of Cardiovascular Diseases, 2020
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- The pre-therapeutic classification of co-morbidity in chronic diseaseJournal of Chronic Diseases, 1970